Microscopic View
Tags
Immuno-Oncology

ichorbio is pleased to announce the release of our first list of all antibodies that are in discovery studies, preclinical and clinical trials. We're currently corresponding with as many biotech firms as we can to add their own candidates into this list. If you see that we're missing yours please contact us at hello@ichor.bio and we'll update our data immediately. 

If you'd like to get this table as an Excel spreadsheet please click here. 

Target Scientific Name Companies Involved Phase in Clinical Trials
4-1BB Urelumab Bristol-Myers Squibb;National Cancer Institute (USA);Ono Pharmaceutical;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;University of Chicago;Medarex Approved
4-1BB Utomilumab Dana-Farber Cancer Institute;Immatics US;Kite Pharma;Kyowa Hakko Kirin;M. D. Anderson Cancer Center;Pfizer Approved
a5b1 Integrin Volociximab Abbott Biotherapeutics Corp;Biogen Idec;IVERIC bio;National Cancer Institute (USA);PDL BioPharma Discontinued
Activin A Garetosmab Regeneron Phase 3
ACVR2B Bimagrumab MorphoSys;Novartis Approved
ACVRL1 Ascrinvacumab Duke University Medical Center;Fondazione IRCCS Istituto Nazionale dei Tumori;Pfizer;Suzhou Kintor Pharmaceuticals Discontinued
ADCYAP1R1 Zelminemab Amgen Approved
ADM Enibarcimab Adrenomed Approved
ADPRC Modakafusp Takeda Approved
ALCAM Praluzatamab CytomX Therapeutics;Immunogen Approved
alpha toxin Atidortoxumab Adimab;Arsanis;X4 Pharmaceuticals Discontinued
AMHR2 Murlentamab LFB Biotechnologies;GamaMabs Pharma Approved
Amyloid Anselamimab Caelum Biosciences Phase 3
Amyloid Birtamimab Onclave Therapeutics Limited, subsidiary of Prothena Phase 3
Amyloid beta Remternetug Eli Lilly Phase 3
Angiopoietin 2 Nesvacumab Regeneron Pharmaceuticals;Sanofi Discontinued
Angiopoietin-like 3 Evinacumab Regeneron Pharmaceuticals Approved
ANGPT2 Trebananib Amgen #N/A
ANGPT2 Zansecimab Eli Lilly Discontinued
ANGPTL3 Evinacumab Regeneron Pharmaceuticals;Sanofi Approved
anthrax protective antigen Obiltoxaximab Elusys Therapeutics
AOC3 Timolumab Acorda Therapeutics;Biotie Therapies Corp.;Seikagaku Corporation Discontinued
APCS Dezamizumab Pentraxin Therapeutics;GlaxoSmithKline Discontinued
APP Aducanumab Biogen;Neurimmune Approved
APP Bapineuzumab JANSSEN Alzheimer Immunotherapy;Pfizer;Wyeth;Elan Corporation Discontinued
APP Crenezumab AC Immune;Genentech;Universidad de Antioquia Approved
APP Donanemab Eli Lilly Approved
APP Gantenerumab MorphoSys;Chugai Pharmaceutical;Roche Approved
APP Lecanemab Biogen;Eisai Approved
APP Ponezumab Rinat Neuroscience;Pfizer Discontinued
APP Solanezumab Eli Lilly Approved
APRIL Sibeprenlimab Otsuka Pharmaceutical Phase 3
APRIL Zigakibart Novartis / Chinook Therapeutics, Inc. Phase 3
AXL Enapotamab Genmab Discontinued
Axl Tilvestamab BerGenBio Approved
AXL receptor tyrosine kinase Mecbotamab vedotin BioAlta LLC Phase 2 (potentially pivotal)
B. anthrasis PA Raxibacumab GlaxoSmithKline Approved
B7-H3 Vobramitamab duocarmazine Macrogenics Phase 2/3
B7-H4 Alsevalimab Five Prime Therapeutics Approved
BAFF Belimumab GlaxoSmithKline Approved
BAFF Receptor Ianalumab MorphoSys Phase 2/3 and Phase 3
BCMA Belantamab GlaxoSmithKline Approved
BCMA, CD3 Elranatamab Pfizer Approved
BCMA, CD3 Linvoseltamab Regeneron Phase 2 (potentially pivotal)
BCMA, CD3 Teclistamab Genmab;Janssen Research & Development Approved
BDCA2 Litifilimab Biogen Phase 2/3 and Phase 3
Bet Pollen Antigen 1 Bremzalerbart Regeneron Pharmaceutical Approved
Bet v 1 Atisnolerbart Regeneron Approved
Bet v 1 Umesolerbart Regeneron Approved
Bet v1 Atisnolerbart, bremzalerbart, umesolerbart Regeneron Phase 3
BK virus AntiBKV Memo Therapeutics AG Phase 2/3
BTLA Tifcemalimab Shanghai Junshi Biosciences Approved
C. difficile exotoxin TcdB Cocktail of biologics Lumen Bioscience, Inc. Phase 2/3 pending
C1q ANX005 Annexon Biosciences Phase 3
C1S Riliprubart TBC Approved
C1s Sutimlimab Bioverativ;True North Therapeutics
C5 Crovalimab Chugai Pharmaceutical;Roche Approved
C5 Gefurulimab Alexion Pharmaceuticals, Inc. Phase 3
C5 Olendalizumab Alexion Pharmaceuticals Discontinued
C5 Pozelimab Alnylam Pharmaceuticals;Regeneron Pharmaceuticals Approved
C5 Ravulizumab Alexion Pharmaceuticals Approved
C5 Tesidolumab MorphoSys;Novartis Approved
C5 Vensobafusp TBC Approved
C5 Vilobelimab InflaRX Approved
C5AR1 Avdoralimab Novo Nordisk;Innate Pharma Approved
CA125 Oregovomab Quest PharmaTech Inc. Phase 3
CA9 Girentuximab Centocor Inc;Heidelberg Pharma AG Discontinued
CA9 Iodine (124I) girentuximab Centocor Inc;Heidelberg Pharma AG #N/A
CALCA Galcanezumab Eli Lilly
CALCA, CALCB Eptinezumab Alder Biopharmaceuticals Approved
CCL2 Carlumab MorphoSys;Janssen Biotech Discontinued
CCR2 Plozalizumab Millennium;Millennium Pharmaceuticals;Takeda;Takeda Oncology Approved
CCR5 Leronlimab CytoDyn;Progenics Pharmaceuticals;The Scripps Research Institute Approved
CD11 Rovelizumab ICOS Corporation Discontinued
CD11a Efalizumab Genentech;Merck Serono;XOMA
CD14 Atibuclimab ICOS Corporation;Implicit Bioscience Approved
CD140a Tovetumab Cambridge Antibody Technology;MedImmune Discontinued
CD147 Metuzumab Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd Phase 2/3
CD158A Lirilumab Novo Nordisk;Bristol-Myers Squibb;Dana-Farber Cancer Institute;Innate Pharma;National Cancer Institute (USA);Ono Pharmaceutical;PrECOG;University of Texas M. D. Anderson Cancer Center Approved
CD19 Axicabtagene ciloleucel Kite Pharma #N/A
CD19 Coltuximab ravtansine ImmunoGen Discontinued
CD19 Denintuzumab mafodotin Seattle Genetics Phase 1/2
CD19 Duvortuxizumab Janssen Biotech;MacroGenics Discontinued
CD19 Inebilizumab Cellective Therapeutics;MedImmune Approved
CD19 Lisocabtagene maraleucel Bristol-Myers Squibb;Juno Therapeutics Approved
CD19 Loncastuximab ADC Therapeutics Approved
CD19 Tafasitamab MorphoSys;The Ohio State University Comprehensive Cancer Center;Xencor Approved
CD19 Tisagenlecleucel Novartis Approved
CD19 Vadacabtagene leraleucel Bristol-Myers Squibb;Juno Therapeutics Discontinued
CD19, Fc?RIIb Obexelimab Xencor Phase 3
CD194 Mogamulizumab Amgen;Bristol-Myers Squibb;Kagoshima University Dental School;Kyowa Hakko;Kyowa Hakko Kirin;Ono Pharmaceutical Approved
CD2 Alefacept Astellas Pharma US, Inc., Discontinued
CD20 Ibritumomab tiuxetan IDEC Pharmaceuticals Approved
CD20 Obinutuzumab GLYCART Biotechnology;Biogen Idec;Chugai Pharmaceutical;Dana-Farber Cancer Institute;Genentech;Lymphoma Academic Research Organisation;Nippon Shinyaku;OHSU Knight Cancer Institute;Pharmacyclics;Polish Myeloma Consortium;Roche;Thomas Jefferson University;University of Heidelberg;University of Leeds Approved
CD20 Ocrelizumab Genentech Approved
CD20 Ofatumumab Novartis Approved
CD20 Rituximab Biogen;Biogen Idec;Cedars-Sinai Medical Center;Chugai Pharmaceutical;Genentech;Hackensack University Medical Center;Hoosier Cancer Research Network;Janssen Research & Development;M. D. Anderson Cancer Center;Mayo Clinic;Nagoya University;Oregon Health & Science University;Roche;SCRI Development Innovations;Takeda Oncology;University of Gottingen;University of Texas M. D. Anderson Cancer Center;University of Tours;Zenyaku Kogyo Approved
CD20 Tositumomab-I131 GlaxoSmithKline Approved
CD20 Veltuzumab Immunomedics;Weill Cornell Medical College Discontinued
CD20 MIL62 Beijing Mabworks Biotech Co., Ltd. Phase 3
CD20, CD3 Epcoritamab Genmab Approved
CD200 Samalizumab Alexion Pharmaceuticals;The Leukemia & Lymphoma Society Discontinued
CD22 Inotuzumab Alliance for Clinical Trials in Oncology;Cancer Research UK;Case Comprehensive Cancer Center;Children's Oncology Group;Erasmus MC;M. D. Anderson Cancer Center;National Cancer Institute (USA);Pfizer;SWOG;University College London;University of Texas M. D. Anderson Cancer Center;Celltech Group Approved
CD22 Moxetumomab pasudotox AstraZeneca Discontinued
CD22 Pinatuzumab vedotin Genentech;Roche Discontinued
CD22 Suciraslimab Shenzhen Lonn Ryonn Phase 3
CD248 Ontuxizumab Ludwig Institute for Cancer Research;Morphotek;National Cancer Institute (USA) Approved
CD25 Camidanlumab ADC Therapeutics;Genmab Approved
CD25 Daclizumab AbbVie;Biogen;Dana-Farber Cancer Institute;National Cancer Institute (USA);PDL BioPharma Approved
CD257 Tabalumab Eli Lilly Discontinued
CD27 Varlilumab Celldex Therapeutics Inc;Oncothyreon;University of California at San Francisco;University of Virginia Approved
CD274 Bintrafusp alfa Merck;GlaxoSmithKline Discontinued
CD274 Cosibelimab Dana-Farber Cancer Institute;Checkpoint Therapeutics;TG Therapeutics Inc Approved
CD274 Envafolimab Alphamab;3D Medicines;Sun Yat-Sen University Approved
CD274 Manelimab Biocad Discontinued
CD274 Pacmilimab CytomX Therapeutics Approved
CD276 Enoblituzumab MacroGenics;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Approved
CD276 Mirzotamab AbbVie Discontinued
CD276 Omburtamab Memorial Sloan-Kettering Cancer Center;Y-mAbs Therapeutics Approved
CD279 Penpulimab Akeso Biopharma;Chia Tai Tianqing Pharmaceutical Approved
CD28 Lulizumab pegol Bristol Myers Squibb Phase 2
CD3 Muromonab- CD3 Janssen-Cilag Approved
CD30 Brentuximab vedotin Takeda Approved
CD30 Briakinumab Cambridge Antibody Technology;Abbott GmbH & Co. KG Discontinued
CD30 Iratumumab Medarex Discontinued
CD326 Edrecolomab Ajinomoto;Centocor Inc Discontinued
CD33 Actinium (225Ac) lintuzumab satetraxetan Actinium Pharmaceuticals Phase 1
CD33 Gemtuzumab UCB;Celgene Corporation;Pfizer;University of California San Diego Approved
CD33 Vadastuximab Seattle Genetics Discontinued
CD37 Lilotomab Nordic Nanovector Approved
CD37 Lutetium (177lu) lilotomab satetraxetan Nordic Nanovector Phase 1/2
CD37 Naratuximab ImmunoGen;Chronic lymphocytic leukaemia Approved
CD37 Otlertuzumab Trubion Pharmaceuticals;Aptevo Therapeutics Discontinued
CD37 Oxelumab Genentech;Genmab;Roche Discontinued
CD38 Daratumumab Boston Medical Center;Bristol-Myers Squibb;Dana-Farber Cancer Institute;French Innovative Leukemia Organisation;Genentech;Genmab;Janssen Biotech;Janssen Research & Development;M. D. Anderson Cancer Center;Syros Pharmaceuticals Approved
CD38 Felzartamab MorphoSys AG Phase 3
CD38 Felzartamab MorphoSys Approved
CD38 Isatuximab ImmunoGen;Huntsman Cancer Institute;Roche;Sanofi Approved
CD38 Mezagitamab Takeda Approved
CD3E Cevostamab Genentech Approved
CD3E Eluvixtamab Amgen Discontinued
CD3E Emerfetamab Amgen Approved
CD3E Flotetuzumab MacroGenics;Servier Discontinued
CD3E Foralumab Medarex;NovImmune SA;Harvard Medical School;Tiziana Life Sciences Approved
CD3E Obrindatamab MacroGenics Discontinued
CD3E Otelixizumab BTG;GlaxoSmithKline;Tolerx Approved
CD3E Pasotuxizumab Amgen;Bayer HealthCare Pharmaceuticals;Micromet Inc Discontinued
CD3E Plamotamab Xencor Approved
CD3E Solitomab Micromet Inc;Amgen Discontinued
CD3E Tebentafusp Immunocore;MedImmune Approved
CD3E Teplizumab Immune Tolerance Network;MacroGenics;National Institute of Diabetes and Digestive and Kidney Diseases;National Institutes of Health (USA);Provention Bio;Tolerance Therapeutics Approved
CD3E Tepoditamab Genmab;Janssen Research & Development Discontinued
CD3E Tidutamab ICON;Xencor Discontinued
CD3E Vibecotamab Xencor Discontinued
CD3E/CD19 Blinatumomab Amgen;Astellas Pharma;M. D. Anderson Cancer Center;Merck & Co;Micromet Inc;National Cancer Institute (USA);University of California Davis Approved
CD3E/CD20 Glofitamab Roche Approved
CD3E/CD20 Mosunetuzumab Genentech Approved
CD3E/CD20 Odronextamab Regeneron Pharmaceuticals Approved
CD4 Ibalizumab Biogen Idec;TaiMed Biologics;Theratechnologies
CD4 Semzuvolimab United Biopharma Phase 3
CD4 Tregalizumab Biotest AG Discontinued
CD40 Bleselumab Kirin Brewery;Astellas Pharma;Kyowa Hakko Kirin Discontinued
CD40 Dacetuzumab Seattle Genetics Discontinued
CD40 Giloralimab AbbVie Approved
CD40 Iscalimab Novartis;XOMA Approved
CD40 Lucatumumab Novartis;XOMA Discontinued
CD40 Mitazalimab Alligator Bioscience;Janssen Biotech Approved
CD40 Ravagalimab AbbVie Approved
CD40 Selicrelumab Abramson Cancer Center of the University of Pennsylvania;Roche Discontinued
CD40 Sotigalimab Apexigen Approved
CD40L Dapirolizumab pegol UCB Phase 3
CD40LG Letolizumab Bristol-Myers Squibb;H. Lee Moffitt Cancer Center and Research Institute Approved
CD45 Apamistamab-Iodine (131I) Actinium Pharmaceuticals Phase 3
CD47 Lemzoparlimab I-Mab Biopharma Co. Ltd. Phase 3
CD47 Letaplimab Innovent Biologics Approved
CD47 Ligufalimab Akeso Biopharma Approved
CD47 Magrolimab Gilead Sciences Phase 3
CD47 Ontorpacept Pfizer Phase 1/2
CD47 Urabrelimab Surface Oncology Discontinued
CD51 Abituzumab Merck Approved
CD52 Alemtuzumab Bayer HealthCare Pharmaceuticals Inc.;Dana-Farber Cancer Institute;German CLL Study Group;Ohio State University Comprehensive Cancer Center;Sanofi;Sanofi Oncology;University of Cologne;University of Cambridge Approved
CD52 Gatralimab Sanofi Discontinued
CD6 Itolizumab Center of Molecular Immunology;Biocon;Biotech Pharmaceutical;Equillium Approved
CD62 Crizanlizumab; crizanlizumab-tmca Novartis Approved
CD70 Cusatuzumab arGEN-X Approved
CD70 Vorsetuzumab Seattle Genetics Discontinued
CD73 Mupadolimab Corvus Pharmaceuticals Approved
CD73 Oleclumab MedImmune;AstraZeneca;European Network of Gynaecological Oncological Trial Groups;Jules Bordet Institute Approved
CD74 Milatuzumab Immunomedics Discontinued
CD79b Polatuzumab Chugai Pharmaceutical;Genentech;Roche Approved
CD80 Belatacept Bristol Myers Squibb #N/A
CEA/CD3 Cibisatamab Roche Approved
CEACAM5 Cergutuzumab amunaleukin Roche Phase 1
CEACAM5 Labetuzumab govitecan Immunomedics Phase 1/2
CEACAM5 Tusamitamab Sanofi-Aventis Approved
CEACAM5 Tusamitamab ravtansine ImmunoGen Phase 3
CEACAM6 Tinurilimab Bayer;German Cancer Research Center Discontinued
CFD Lampalizumab Tanox;Genentech Discontinued
CGRP Fremanezumab Rinat Neuroscience;Teva Pharmaceutical Industries Approved
CGRP receptor Erenumab Amgen;Novartis
Claudin 18.2 Zolbetuximab Ganymed Pharmaceuticals Approved
Clostridium difficile enterotoxin B Bezlotoxumab Medarex;University of Massachusetts Medical School;Merck & Co;Merck Sharp & Dohme
CNR1 Nimacimab Bird Rock Bio Approved
complement C3b, C4b Mirococept #N/A #N/A
Complement protein C5 Eculizumab Alexion Pharmaceuticals;Brigham and Womens Hospital;Chiba University;Handok Inc Approved
CSF-1R Axatilimab Syndax Pharmaceuticals, Inc Phase 2 (pivotal)
CSF1 Lacnotuzumab Dana-Farber Cancer Institute;Novartis;Novartis Oncology;Seoul National University Hospital Approved
CSF1R Cabiralizumab Apexigen;Bristol-Myers Squibb;Five Prime Therapeutics;University of Chicago;Yale University Approved
CSF1R Emactuzumab Roche;University of Texas M. D. Anderson Cancer Center Approved
CSF2 Gimsilumab Ludwig Institute for Cancer Research;Morphotek Discontinued
CSF2 Lenzilumab Humanigen;KaloBios Pharmaceuticals Approved
CSF2 Namilumab Micromet Inc;Izana Bioscience;Takeda Pharmaceuticals International GmbH Approved
CSF2 Otilimab GlaxoSmithKline;MorphoSys Discontinued
CSF2RA Mavrilimumab Zenyth Therapeutics Kiniksa Pharmaceuticals;MedImmune Approved
CSF2RB Trabikibart TBC Approved
CSF3R Anumigilimab CSL Behring Approved
CSF3R Pegfilgrastim #N/A #N/A
CTGF Pamrevlumab FibroGen Approved
CTLA-4 Gotistobart OncoC4, Inc Phase 3
CTLA-4 Ipilimumab Aduro BioTech;AIO Studien gGmbH;Australian and New Zealand Urogenital and Prostate Cancer Group;Bavarian Nordic;Big Ten Cancer Research Consortium;BioGene Pharmaceutical;Bristol-Myers Squibb;Canadian Cancer Trials Group;Dana-Farber Cancer Institute;European Thoracic Oncology Platform;Grupo Espanol Multidisciplinar de Melanoma;Icahn School of Medicine at Mount Sinai;Intergroupe Francophone de Cancerologie Thoracique;Ludwig Institute for Cancer Research;Massachusetts General Hospital;Medarex;Memorial Sloan-Kettering Cancer Center;National Cancer Institute (USA);National University Hospital (Singapore);Northwestern University;Olivia Newton-John Cancer Research Institute;OncoTherapy Science;Ono Pharmaceutical;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;University College London;University of California at San Francisco;University of Texas M. D. Anderson Cancer Center Approved
CTLA-4 Nurulimab Biocad Phase 3
CTLA-4 Quavonlimab Akeso Biopharma Phase 3
CTLA-4 Tremelimumab AIO Studien gGmbH;Amgen;ARCAGY/GINECO Group;AstraZeneca;Azienda Ospedaliera Universitaria Senese;Canadian Cancer Trials Group;Charite - Universitatsmedizin Berlin;Dana-Farber Cancer Institute;Fondazione IRCCS Istituto Nazionale dei Tumori;Grupo Espanol de Tumores Neuroendocrinos;Hoosier Cancer Research Network;Immunocore;Institute Gustave-Roussy;Kyoto Breast Cancer Research Network;M. D. Anderson Cancer Center;MedImmune;Memorial Sloan-Kettering Cancer Center;National Cancer Institute (USA);Northwestern University;Pfizer;Seoul National University Hospital;UNICANCER;University College London;University of Maryland Greenbaum Cancer Center;Yonsei University College of Medicine Approved
CTLA-4 Fc Fusion Protein Abatacept #N/A #N/A
CTLA4 Zalifrelimab 4-Antibody;Ludwig Institute for Cancer Research;Agenus;Recepta biopharma Approved
CX3CL1 Quetmolimab KAN Research Institute;EA Pharma;Eisai Co Ltd Approved
CXCL10 Eldelumab Bristol-Myers Squibb;Medarex Discontinued
CXCR4 Ulocuplumab Bristol-Myers Squibb;Medarex;University of Bari Approved
Dabigatran Idarucizumab Boehringer Ingelheim Approved
DKK1 Sirexatamab Leap Therapeutics Approved
DLL3 Rovalpituzumab Bristol-Myers Squibb;Stemcentrx Discontinued
DLL3, CD3 Tarlatamab Amgen Phase 2 (potentially pivotal)
DLL4 Demcizumab Celgene Corporation;OncoMed Pharmaceuticals Discontinued
DLL4 Enoticumab Regeneron Pharmaceuticals;Sanofi Discontinued
DLL4, VEGF Navicixizumab OncXerna Theraputics, Inc. Phase 3 pending
DLL4, VEGF National OncoVenture Phase 2/3
DNA/histone Iodine (131I) derlotuximab biotin #N/A #N/A
DPEP3 Tamrintamab Stemcentrx Approved
DPP4 Begelomab ADIENNE Approved
DR5 Ozekibart Inhibrx, Inc. Phase 2 (pivotal)
Ebola virus Ansuvimab-zykl Approved
EDNRA Patecibart TBC Approved
EGFL7 Parsatuzumab Chugai Pharmaceutical;Genentech Discontinued
EGFR Amivantamab Genmab;Janssen Research & Development Approved
EGFR Cetuximab Array BioPharma;Bristol-Myers Squibb;Celldex Therapeutics Inc;Centre Jean Perrin;Eli Lilly;Merck KGaA;New York University School of Medicine;Novartis;Pierre Fabre;Roche;University Hospital Ghent;University of California;University of Heidelberg;University of Michigan Comprehensive Cancer Center Approved
EGFR Cetuximab sarotalocan #N/A #N/A
EGFR Demupitamab Sinocelltech Approved
EGFR Depatuxizumab Ludwig Institute for Cancer Research;AbbVie Discontinued
EGFR Futuximab Symphogen;Merck Approved
EGFR Imgatuzumab GLYCART Biotechnology;Roche Discontinued
EGFR Laprituximab ImmunoGen Discontinued
EGFR Losatuxizumab AbbVie Discontinued
EGFR Modotuximab Symphogen;Merck Approved
EGFR Necitumumab ImClone Systems;Eli Lilly Approved
EGFR Nimotuzumab Biocon Biopharmaceuticals;Biotech Pharmaceutical;Center of Molecular Immunology;CIMYM;Daiichi Sankyo Inc;Eurofarma;Gilead Sciences;Innogene Kalbiotech;InnoMab;Kuhnil Pharmaceutical Company;Laboratorios Pisa;Oncoscience Approved
EGFR Panitumumab Approved
EGFR Petosemtamab Merus Discontinued
EGFR Serclutamab AbbVie Discontinued
EGFR Tomuzotuximab Glycotope Approved
EGFR Shanghai Miracogen Inc. Phase 3
EGFR, HER3 Izalontamab Biokin Phase 2/3
endogenous retrovirus Temelimab GeNeuro Approved
ENG Carotuximab National Cancer Institute (USA);Santen Pharmaceutical;TRACON Pharmaceuticals;University of Alabama at Birmingham;University of Minnesota;Roswell Park Cancer Institute Discontinued
ENTPD1 Perenostobart Surface Oncology;Arcus Biosciences Approved
Enzyme substitute Asfotase alfa #N/A #N/A
EPCAM Citatuzumab bogatox #N/A #N/A
EPCAM Oportuzumab monatox #N/A #N/A
EPCAM/CD3 Catumaxomab Approved
EPHA3 Ifabotuzumab Ludwig Institute for Cancer Research;Humanigen;Olivia Newton-John Cancer Research Institute Approved
ERA Docaravimab Candila Healthcare Approved
ERA Miromavimab Candila Healthcare
ERBB2 Cinrebafusp Eli Lilly Approved
ERBB2 Cinrebafusp alfa #N/A #N/A
ERBB2 Disitamab Yantai Rongchang Biological Engineering Approved
ERBB2 Gancotamab Merrimack Pharmaceuticals;HERMES BioSciences Discontinued
ERBB2 Timigutuzumab Roche
ERBB2 Trastuzumab deruxtecan #N/A
ERBB2 Trastuzumab duocarmazine #N/A
ERBB2 Trastuzumab emtansine #N/A
ERBB2 Zanidatamab Zymeworks Approved
ERBB2 Zenocutuzumab Merus Approved
ERBB3 Duligotuzumab Genentech;Roche Discontinued
ERBB3 Elgemtumab MorphoSys;Novartis;Memorial Sloan-Kettering Cancer Center;Novartis Oncology Discontinued
ERBB3 Lumretuzumab Roche Discontinued
ERBB3 Patritumab Amgen;U3 Pharma;Daiichi Sankyo Company Approved
ERBB3 Seribantumab Merrimack Pharmaceuticals;Sanofi Discontinued
EREG Fepixnebart Eli Lilly and Company Approved
F11 Osocimab Bayer HealthCare Discontinued
F3 Tisotumab Genmab;Seattle Genetics Approved
F9xF10 Emicizumab Chugai Pharmaceutical;Roche
Factor IXa, Factor X Novo Nordisk A/S Phase 3
Factor substitute Albutrepenonacog alfa #N/A #N/A
Factor substitute Dalcinonacog alfa #N/A #N/A
Factor substitute Oreptacog alfa #N/A #N/A
Factor XI Abelacimab Novartis Phase 3
Factor XIIa Garadacimab CSL Behring Phase 3
FAP Simlukafusp alfa #N/A #N/A
FASLG Asunercept #N/A #N/A
FCGRT Batoclimab Immunovant Sciences Approved
FCGRT Orilanolimab Syntimmune Discontinued
FCGRT Rozanolixizumab UCB Approved
FcRn Nipocalimab Janssen Phase 2/3 and Phase 3
Fel d 1 Freneslerbart Regeneron Pharmaceuticals Approved
Fel d 1 Mevonlerbart Regeneron Approved
Felcat IL31 Dovanvetmab na Approved
Felcat NGF Frunevetmab Nexvet Approved
Felcat NGF Relfovetmab TBC Approved
FGF23 Burosumab Kyowa Hakko Kirin;Ultragenyx Pharmaceutical Approved
FGFR1 Pegbelfermin #N/A #N/A
FGFR2 Aprutumab ixadotin #N/A #N/A
FGFR2b Aprutumab Bayer Discontinued
FGFR2b Bemarituzumab Amgen Phase 3
FGFR2b Bemarituzumab Five Prime Therapeutics;ZAI Lab Approved
FGFR3 Vofatamab BioClin Therapeutics;Rainier Therapeutics Approved
FGFR4 Aldafermin #N/A #N/A
Fibronectin Onfekafusp alfa Philogen S.p.A. Phase 3
FLT1 Icrucumab ImClone Systems Discontinued
FN Bifikafusp alfa #N/A #N/A
FN Radretumab Philogen Discontinued
Folate receptor alpha Luveltamab tazevibulin Sutro Biopharma Phase 2/3
FOLR1 Farletuzumab Ludwig Institute for Cancer Research;Morphotek;Eisai Co Ltd Discontinued
FOLR1 Mirvetuximab ImmunoGen;National Comprehensive Cancer Network Approved
frizzled family receptor Vantictumab Bayer HealthCare Pharmaceuticals;OncoMed Pharmaceuticals Discontinued
FZD10 Tabituximab OncoTherapy Science;Centre Leon Berard Discontinued
ganglioside GD2 Dinutuximab National Cancer Institute (USA);New Approaches to Neuroblastoma Therapy Consortium;St. John of God Foundation;United Therapeutics Corporation Approved
ganglioside GD2 Dinutuximab beta #N/A #N/A
Ganglioside GD2 Naxitamab Memorial Sloan-Kettering Cancer Center;Y-mAbs Therapeutics Approved
GCGR Crotedumab Regeneron Pharmaceuticals;Sanofi Discontinued
GCGR Volagidemab Amgen;REMD Biotherapeutics Approved
GDF11 Luspatercept #N/A #N/A
GDF15 Ponsegromab Pfizer Discontinued
GDF15 Visugromab CatalYm Approved
GDF2 Dalantercept #N/A #N/A
GFRA3 Nadecnemab Regeneron Pharmaceuticals Approved
GLP-1R Gmax Biopharm Australia Pty Ltd Phase 3
GLP1R Albiglutide #N/A #N/A
GLP1R Dulaglutide #N/A #N/A
Glycoprotein VI Glenzocimab Acticor Biotech Phase 2/3
GPC3 Codrituzumab Perseus Proteomics;Chugai Pharmaceutical;Roche Approved
GPIIb/IIIa Abciximab Approved
GPNMB Glembatumumab CuraGen Corporation;Celldex Therapeutics Inc;National Cancer Institute (USA) Discontinued
GPRC5D, CD3 Talquetamab Genmab;Janssen Research & Development Approved
GREM1 Ginisortamab UCB Approved
GUCY2C Indusatumab Millennium;Takeda Oncology Discontinued
HAVCR2 Cobolimab AnaptysBio;GlaxoSmithKline;TESARO Approved
HBV Lenvervimab Green Cross;GC Pharma;AbbVie Approved
heat shock protein 90 homolog Efungumab NeuTec Pharma Discontinued
HER2 [fam-]trastuzumab deruxtecan, fam-trastuzumab deruxtecan-nxki Approved
HER2 Ado-trastuzumab emtansine Approved
HER2 Anbenitamab Jiangsu Alphamab Biopharmaceuticals Co., Ltd Phase 2/3 (Phase 3 not yet recruiting)
HER2 Anvatabart opadotin Ambrx Phase 2/3
HER2 Margetuximab Raven biotechnologies;GC Pharma;Green Cross;MacroGenics;Merck Sharp & Dohme Approved
HER2 Pertuzumab Chugai Pharmaceutical;Dana-Farber Cancer Institute;FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCC DI CANDIOLO;Genentech;International Breast Cancer Study Group;Japan Breast Cancer Research Group;Medica Scientia Innovation Research;Roche;West German Study Group Approved
HER2 Trastuzumab Roche
HER2 Trastuzumab botidotin Kelun-Biotech, subsidiary Klus Pharma Phase 2 (pivotal) and phase 3
HER2 Trastuzumab duocarmazine Approved
HER2 Trastuzumab rezetecan Jiangsu HengRui Medicine Co., Ltd. Phase 3
HER2 CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Phase 3 pending
HER2 LegoChem Biosciences, Inc. Phase 3
HER2 Shanghai Miracogen Inc. Phase 2/3
HER2 SUNHO（China）BioPharmaceutical CO., Ltd. or Beijing Sunho Pharmaceutical Co. Phase 2/3 pending
HGF Ficlatuzumab AVEO Oncology;AVEO Pharmaceuticals;Dana-Farber Cancer Institute;University of Arizona Cancer Center;University of California at San Francisco Approved
HGF Rilotumumab Amgen;Astellas Pharma Discontinued
HIV-1 Alvircept sudotox #N/A #N/A
HIV-1 Elipovimab Gilead Sciences Discontinued
HIV-1 Suvizumab Kaketsuken;Kumamoto University;University of Missouri-Columbia Discontinued
ICAM1 Bersanlimab BioInvent International Discontinued
ICOS Feladilimab GlaxoSmithKline Approved
ICOS Vopratelimab Jounce Therapeutics Approved
ICOSLG Prezalumab Amgen;MedImmune Discontinued
ICOSLG Rozibafusp alfa #N/A #N/A
idiotope of anti- Racotumomab Center of Molecular Immunology;Elea;Innogene Kalbiotech;Recombio Approved
IFN-gamma Emapalumab NovImmune SA;Swedish Orphan Biovitrum
IFN-β Dazukibart Pfizer Inc. Phase 3
IFNA1 Bifarcept #N/A #N/A
IFNA1 Rontalizumab Chugai Pharmaceutical;Genentech Discontinued
IFNA1 Sifalimumab Medarex;MedImmune Discontinued
IFNAR1 Albinterferon alfa-2b #N/A #N/A
IFNAR1 Anifrolumab Medarex;Medical University of Vienna;MedImmune Approved
IFNAR1 Peginterferon alfacon-2 #N/A #N/A
IFNAR1 Sampeginterferon beta-1a #N/A #N/A
IFNAR1_IFNAR2 Interferon alfacon-1 #N/A #N/A
IgE Ligelizumab Tanox Phase 3
IgE Omalizumab Dana-Farber Cancer Institute;Genentech;John Hopkins University;Novartis Approved
IGF-1R Innovent Biologics, Inc Phase 2/3
IGF-1R Viridian Therapeutics, Inc. Phase 2/3
IGF1R Cixutumumab Eli Lilly;ImClone Systems;M. D. Anderson Cancer Center;National Cancer Institute (USA) Discontinued
IGF1R Dalotuzumab Pierre Fabre;Merck & Co Discontinued
IGF1R Figitumumab Pfizer Discontinued
IGF1R Ganitumab Amgen;Millennium;NantWorks;National Cancer Institute (USA);Novartis;Takeda;Takeda Oncology;UCLAs Jonsson Comprehensive Cancer Center Discontinued
IGF1R Istiratumab Adimab;Merrimack Pharmaceuticals Discontinued
IGF1R Robatumumab Merck & Co;Schering-Plough Discontinued
IGF1R Teprotumumab Genmab;Roche;Horizon Therapeutics plc Approved
IGF2 Dusigitumab MedImmune Discontinued
IGF2 Xentuzumab Boehringer Ingelheim;Eli Lilly Approved
IGHE Quilizumab Genentech Discontinued
IL-12/23 Ustekinumab Approved
IL-12/23p40 Ebdarokimab Akesobio Australia Pty Ltd Phase 3
IL-13 Cendakimab AbbVie Phase 3
IL-13 Lebrikizumab Chugai Pharmaceutical;Comprehensive Clinical Research Network;Dermira;Genentech;Roche;Tanox Approved
IL-13 Tralokinumab Cambridge Antibody Technology;Icahn School of Medicine at Mount Sinai;LEO Pharma;MedImmune Approved
IL-17 Brodalumab Amgen;AstraZeneca;Bausch Health Companies;Kyowa Hakko Kirin;LEO Pharma Approved
IL-17A Ixekizumab Eli Lilly;Oregon Health & Science University;Torii Pharmaceutical Approved
IL-17A Vunakizumab Atridia Pty Ltd./ Jiangsu Hengrui Medicine Co. Phase 2/3 and Phase 3
IL-17A Xeligekimab Genrix (Shanghai) Biopharmaceutical Co. Ltd. Phase 3
IL-17A 3SBio Phase 3
IL-1B Gevokizumab IRIS;National Eye Institute;North Shore-Long Island Jewish Health System;Novartis;Servier;University of Zurich;XOMA Approved
IL-20 Fletikumab ZymoGenetics;Novo Nordisk Discontinued
IL-22 Fezakinumab Pfizer;Wyeth Discontinued
IL-23 Guselkumab Janssen Biotech;MorphoSys;Taiho Pharmaceutical Approved
IL-23 p19 Picankibart Innovent Biologics (Suzhou) Co. Ltd. Phase 3
IL-2R Basiliximab Approved
IL-31RA Nemolizumab Chugai Pharmaceutical;Galderma;Maruho Approved
IL-33 Etokimab AnaptysBio Discontinued
IL-33 Itepekimab Regeneron Phase 3
IL-33 Tozorakimab AstraZeneca/MedImmune Phase 3
IL-33R Astegolimab Hoffmann-La Roche Phase 2/3
IL-36R Imsidolimab AnaptysBio, Inc. Phase 3
IL-3R Tagraxofusp Stemline Therapeutics Approved
IL-3RA Pivekimab ImmunoGen Approved
IL-4R alpha Dupilumab Aimmune Therapeutics;Regeneron Pharmaceuticals;Sanofi Approved
IL-4Rα Keymed Biosciences Co. Ltd Phase 3
IL-4Rα Suzhou Connect Biopharmaceuticals, Ltd. Phase 2 (pivotal)
IL-5 Depemokimab GlaxoSmithKline Phase 3
IL-5 Mepolizumab Approved
IL-6 Clazakizumab Alder Biopharmaceuticals;Cedars-Sinai Medical Center;Medical University of Vienna;Vitaeris Approved
IL-6 Olokizumab R-Pharm;UCB Approved
IL-6 Siltuximab Centocor Inc;Janssen Biotech;Memorial Sloan-Kettering Cancer Center Approved
IL-6 Hoffmann-La Roche Phase 3
IL-6 receptor Tocilizumab Assistance Publique Hopitaux de Paris;Charite - Universitatsmedizin Berlin;Chugai Pharmaceutical;Hospital for Special Surgery;JW Pharmaceutical;Roche;University Hospital Inselspital;University Hospital;Osaka University Tubingen;University of Bern;University of Pittsburgh Approved
IL-6R Sarilumab Asahi Kasei Pharma Corp;Regeneron Pharmaceuticals;Sanofi Approved
IL-6R Satralizumab Chugai Pharmaceutical;Roche
IL-7RA Lusvertikimab OSE Immunotherapeutics Approved
IL-9 Enokizumab Genaera Corporation;Ludwig Institute for Cancer Research;MedImmune Discontinued
IL12B Ustekinumab Centocor Inc;Janssen Biotech;Medarex Approved
IL13 Abrezekimab UCB Discontinued
IL13 Anrukinzumab Pfizer;Wyeth Discontinued
IL13 Cendakimab Abbott Laboratories;AbbVie;Receptos Approved
IL13 Dectrekumab Novartis Discontinued
IL13RA1 Eblasakimab ASLAN Pharmaceuticals Approved
IL15 Inbakicept #N/A #N/A
IL15RA Nogapendekin alfa #N/A #N/A
IL17A Afasevikumab NovImmune;Genentech Discontinued
IL17A Bimekizumab UCB Approved
IL17A Netakimab CJSC Biocad Approved
IL17A Perakizumab Roche Discontinued
IL17A Secukinumab Beth Israel Deaconess Medical Center;GWT-TUD GmbH;Icahn School of Medicine at Mount Sinai;Novartis;Alcon Approved
IL17A Sonelokimab #N/A #N/A
IL17A Tibulizumab Eli Lilly Discontinued
IL1A Bermekimab XBiotech Inc. Approved
IL1A Vilamakitug XBiotech USA, Inc Approved
IL1B Canakinumab Charite - Universitatsmedizin Berlin;Novartis;Triemli hospital;University Hospital Tubingen;University Hospital Zurich Approved
IL1B Lutikizumab Abbott Laboratories;AbbVie Discontinued
IL1B Rilonacept #N/A #N/A
IL1RAP Nadunolimab Lund University;Cantargia Approved
IL1RL1 Astegolimab Amgen;Genentech;University of Leicester Approved
IL1RL2 Denileukin diftitox #N/A #N/A
IL2 Aldesleukin #N/A #N/A
IL21 Avizakimab MedImmune;Boston Pharmaceuticals Approved
IL23A Brazikumab Allergan;Amgen;AstraZeneca Approved
IL23A Mirikizumab Eli Lilly Approved
IL23A Risankizumab AbbVie;Boehringer Ingelheim Approved
IL23A Tildrakizumab Almirall S.A.;Merck & Co;Schering-Plough;Sun Pharmaceutical Industries Approved
IL2RB Bempegaldesleukin #N/A #N/A
IL33 Torudokimab Eli Lilly Approved
IL36RN Spesolimab Boehringer Ingelheim Approved
IL3RA Talacotuzumab CSL;Janssen Biotech Approved
IL4 Romilkimab Sanofi Discontinued
IL4R Manfidokimab Akeso Biopharma Approved
IL4R Rademikibart TBC Approved
IL4R Stapokibart TBC Approved
IL5 Reslizumab Celltech R&D;Schering-Plough;Allergy and Asthma Clinical Research;Celltech R&D;Teva Pharmaceutical Industries Approved
IL5 Varokibart Teva Pharmaceutical Approved
IL5RA Benralizumab AstraZeneca;Cincinnati Children's Hospital Medical Center;Kyowa Hakko;Kyowa Hakko Kirin;McMaster University;MedImmune;National Jewish Medical and Research Center;BioWa Approved
IL6 Olamkicept #N/A #N/A
IL6 Sirukumab Centocor Inc;GlaxoSmithKline;Janssen Biotech Approved
IL6 Ziltivekimab AstraZeneca;Corvidia Approved
IL6R Levilimab Biocad Approved
IL6R Vobarilizumab Ablynx Discontinued
influenza A virus hemagglutinin HA Firivumab Celltrion Discontinued
influenza A virus hemagglutinin HA Gedivumab Genentech Discontinued
influenza A virus hemagglutinin HA Navivumab Celltrion Discontinued
influenza A virus hemagglutinin HA2 subunit from various strains Diridavumab National Institute of Allergy and Infectious Diseases;Crucell Approved
influenza B virus hemagglutinin Lesofavumab Genentech Discontinued
INHBA Sotatercept #N/A #N/A
INSR Valanafusp alfa #N/A #N/A
Interferon Mipeginterferon alfa-2b PharmaEssentia Approved
ITGA2 Vatelizumab Chromos Molecular Systems;Glenmark Pharmaceuticals S.A.;Sanofi Discontinued
ITGA2B_ITGB3 Tadocizumab PDL BioPharma;Yamanouchi Discontinued
ITGA4 Natalizumab Biogen;Biogen Idec;Elan Corporation;Perrigo Approved
ITGA4/ITGB7 Abrilumab Amgen;AstraZeneca Discontinued
ITGA4/ITGB7 Etrolizumab Genentech;Roche Approved
ITGAV_ITGB3 Etaracizumab Applied Molecular Evolution;MedImmune Discontinued
ITGAV_ITGB3 Intetumumab Centocor Inc;Janssen Biotech;Janssen-Cilag Discontinued
KDR Alacizumab pegol #N/A #N/A
KDR Olinvacimab PharmAbcine;3SBio Approved
KDR Pegdinetanib #N/A #N/A
KIR3DL2 Lacutamab University of Genoa;Innate Pharma Approved
KLKB1 Lanadelumab Dyax;Shire;Takeda
KLRG1 Ulviprubart Abcuro, Inc. Phase 2/3
KLRK1 Tesnatilimab Janssen Research & Development Approved
L-Selectin Aselizumab PDL Biopharma Discontinued
LAG-3 Favezelimab Merck Sharp & Dohme Corp. Phase 3
LAG-3 Fianlimab Regeneron Pharmaceuticals Phase 2/3 and Phase 3
LAG-3 Relatlimab Approved
LAG3 Encelimab Anaptys Bio;TESARO Approved
LAG3 Ieramilimab Immutep Limited;Novartis Approved
LAG3 Miptenalimab Boehringer Ingelheim Approved
LAG3 Relatlimab Bristol-Myers Squibb;Ono Pharmaceutical;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Approved
LEPR Mibavademab Regeneron Pharmaceuticals Approved
LGALS3 Oloctinebart TBC Approved
LHCGR Choriogonadotropin beta #N/A #N/A
LILRA4 Daxdilimab Viela Bio Approved
LILRB2 Polzastobart Jounce Therapeutics Approved
LILRB4 Rolistobart TBC Approved
LINGO1 Opicinumab Biogen Idec;Dyax;Biogen Discontinued
LOXL2 Simtuzumab Arresto Biosciences;Gilead Sciences Discontinued
LRRC15 Samrotamab AbbVie Approved
LRRC32 Livmoniplimab AbbVie Approved
LTA Baminercept #N/A #N/A
LTA Pateclizumab Genentech Discontinued
LukGH Berlimatoxumab Adimab;Arsanis;X4 Pharmaceuticals Discontinued
LYPD3 Lupartumab Bayer HealthCare Discontinued
MADCAM1 Ontamalimab Pfizer;Takeda Discontinued
MAG Refanezumab GlaxoSmithKline Discontinued
MAPT Bepranemab UCB BioPharma Approved
MAPT Gosuranemab Biogen;Bristol-Myers Squibb;iPierian Discontinued
MAPT Semorinemab AC Immune;Genentech Approved
MAPT Tilavonemab AbbVie;C2N Diagnostics Approved
MAPT Zagotenemab Eli Lilly Discontinued
MASP2 Narsoplimab Omeros Approved
MCAM Imaprelimab Neotope Biosciences;Onclave Therapeutics;Prothena;Prothena Corporation Discontinued
MET Emibetuzumab Eli Lilly Approved
MET Onartuzumab Chugai Pharmaceutical;Genentech Discontinued
MET Telisotuzumab Pierre Fabre;AbbVie Discontinued
MIF Imalumab Cytokine PharmaSciences;Baxalta;Shire;Takeda Discontinued
MMP9 Andecaliximab Gilead Sciences Discontinued
mouse anti-idiotype monoclonal antibody Abagovomab Menarini Discontinued
MPL Romiplostim #N/A #N/A
MS4A1 Ocaratuzumab Applied Molecular Evolution;MENTRIK Biotech Discontinued
MS4A1 Ripertamab Sinocelltech Approved
MS4A1 Ublituximab LFB Biotechnologies;rEVO Biologics;Johns Hopkins University;TG Therapeutics Inc Approved
MSLN Amatuximab Eisai Co Ltd;Morphotek;National Cancer Institute (USA) Discontinued
MSLN Anetumab corixetan #N/A #N/A
MSLN Anetumab ravtansine #N/A #N/A
MST1R Narnatumab ImClone Systems;Eli Lilly;ImClone Systems Discontinued
MSTN Domagrozumab Kennedy Krieger Institute;Pfizer Discontinued
MSTN Landogrozumab Eli Lilly Discontinued
MSTN Ramatercept #N/A #N/A
MSTN Taldefgrobep alfa #N/A #N/A
MSTN Trevogrumab Regeneron Pharmaceuticals;Sanofi Approved
MUC1 Clivatuzumab tetraxetan #N/A #N/A
MUC1 Gatipotuzumab NEMOD Biotherapeutics;Glycotope Approved
MUC1 Yttrium (90Y) clivatuzumab tetraxetan #N/A #N/A
MUC1 sialylated carbohydrate tumour-associated Cantuzumab ravtansine #N/A #N/A
MUC16 Sofituzumab vedotin #N/A #N/A
MUC5AC Ensituximab Neogenix Oncology;Duke University Medical Center;H. Lee Moffitt Cancer Center and Research Institute;Johns Hopkins Medical Institutions;Montefiore Medical Center;National Cancer Institute (USA);Precision Biologics;University of North Carolina;University of Texas Southwestern Medical Center;Yale University School of Medicine Approved
Myostatin Apitegromab Scholar Rock Phase 3
Myostatin Chugai Phase 2/3
N/A Bevifimod #N/A #N/A
NaPi2b Upifitamab rilsodotin Mersana Therapeutics Phase 2 (pivotal) and phase 3
NCAM1 Lorvotuzumab mertansine #N/A #N/A
NGF Fasinumab Mitsubishi Tanabe Pharma Corporation;Regeneron Pharmaceuticals;Teva Pharmaceutical Industries;Sanofi Approved
NGF Fulranumab Janssen Pharmaceuticals;Janssen Research & Development;Takeda;Amgen Discontinued
NGF Tanezumab Rinat Neuroscience;Pfizer Approved
NKG2A Monalizumab Innate Pharma;MedImmune;NCIC Clinical Trials Group;Novo Nordisk Approved
NOTCH1 Brontictuzumab OncoMed Pharmaceuticals;University of Texas M. D. Anderson Cancer Center Discontinued
NOTCH2 Tarextumab OncoMed Pharmaceuticals Approved
NRP1 Vesencumab Genentech;Roche Discontinued
NT5E Uliledlimab TRACON Pharmaceuticals;I-Mab Biopharma Approved
OX40 Ivuxolimab Pfizer Inc. Phase 3
OX40 Rocatinlimab Kyowa Hakko Kirin Phase 3
oxLDL Orticumab Abcentra;BioInvent International;Genentech Approved
PcrV protein

type III secretion system		 Gremubamab MedImmune Discontinued
PcrV protein

type III secretion system		 Rivabazumab KaloBios Pharmaceuticals Inc Discontinued
PCSK9 Alirocumab Regeneron Pharmaceuticals;Sanofi;University Hospital Inselspital Approved
PCSK9 Bococizumab Halozyme Therapeutics;Pfizer Discontinued
PCSK9 Evolocumab Amgen;Amgen Astellas BioPharma;University Hospital Inselspital Approved
PCSK9 Frovocimab Eli Lilly Approved
PCSK9 Lerodalcibep #N/A #N/A
PCSK9 Lodelcizumab Novartis Discontinued
PCSK9 Ongericimab Shanghai Junshi Biosciences Approved
PCSK9 Ralpancizumab Pfizer Discontinued
PCSK9 Recaticimab Jiangsu HengRui Medicine Co., Ltd. Phase 3
PCSK9 Tafolecimab Innovent Biologics Approved
PD-1 Acrixolimab Y-Biologics Approved
PD-1 Balstilimab Agenus;Ludwig Institute for Cancer Research Approved
PD-1 Budigalimab AbbVie Approved
PD-1 Camrelizumab Chinese PLA General Hospital;Hangzhou Cancer Hospital;Incyte Corporation;Jiangsu Hengrui Medicine Co.;Nanjing Medical University;Peking University People's Hospital;Sun Yat-Sen University Approved
PD-1 Cemiplimab Inovio Pharmaceuticals;ISA Pharmaceuticals;Regeneron Pharmaceuticals;Sanofi;Sidney Kimmel Cancer Center;SillaJen Biotherapeutics;University of Texas M. D. Anderson Cancer Center Approved
PD-1 Cetrelimab Janssen Research & Development, LLC Phase 3
PD-1 Cetrelimab Janssen Research & Development Approved
PD-1 Dostarlimab AnaptysBio;European Network of Gynaecological Oncological Trial Groups;GlaxoSmithKline;TESARO Approved
PD-1 Enlonstobart TBC Approved
PD-1 Ezabenlimab Boehringer Ingelheim Approved
PD-1 Finotonlimab Sinocelltech Ltd Phase 2/3 and Phase 3
PD-1 Geptanolimab Genor Biopharma Co., Ltd. Phase 2 (pivotal)
PD-1 Iparomlimab Qilu Pharmaceutical Co., Ltd. Phase 2/3
PD-1 Lipustobart Livzon Pharmaceutical Group Approved
PD-1 Lodapolimab Dana-Farber Cancer Institute;Eli Lilly Discontinued
PD-1 Nivolumab Aduro BioTech;AIO Studien gGmbH;Australian and New Zealand Urogenital and Prostate Cancer Group;Barbara Ann Karmanos Cancer Institute;Bavarian Nordic;Big Ten Cancer Research Consortium;Bristol-Myers Squibb;Canadian Cancer Trials Group;Celleron Therapeutics;Clatterbridge Cancer Centre NHS Foundation Trust;Clovis Oncology;Curie Institute;Daiichi Sankyo Company;Dana-Farber Cancer Institute;Duke University Medical Center;Eisai Inc;Eli Lilly;Emory University;European Thoracic Oncology Platform;Exelixis;Frontier Science foundation;Grupo Espanol Multidisciplinar de Melanoma;H. Lee Moffitt Cancer Center and Research Institute;Hellenic Genitourinary Cancer Group;Hoosier Cancer Research Network;HOVON Foundation;Incyte Corporation;Intergroupe Francophone de Cancerologie Thoracique;Janssen Biotech;Janssen Research & Development;Kansai Medical University;Kyoto Breast Cancer Research Network;M. D. Anderson Cancer Center;Massachusetts General Hospital;Medarex;Nantes University Hospital;National Cancer Center (Tokyo);National Cancer Centre (Singapore);National Cancer Institute (USA);Nektar Therapeutics;Neon Therapeutics;Netherlands Cancer Institute;Northwestern University;Ono Pharmaceutical;Pharmacyclics;PrECOG;Seattle Genetics;Sidney Kimmel Cancer Center;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;Syneos Health;The University of Montreal Hospital Research Center;UNICANCER;University College London;University of Liverpool;University of Pittsburgh;University of Texas M. D. Anderson Cancer Center;Vanderbilt-Ingram Cancer Center;Zucero Therapeutics Approved
PD-1 Nofazinlimab Cstone Pharmaceuticals Phase 3
PD-1 Pembrolizumab Aduro BioTech;AIO Studien gGmbH;Amgen;Augusta University;Bayer;BerGenBio;Big Ten Cancer Research Consortium;BioLineRx;Canadian Cancer Trials Group;Celgene Corporation;Columbia University;Dana-Farber Cancer Institute;DNAtrix;Duke University;Eisai Co Ltd;Eli Lilly;Emory University;Fox Chase Cancer Center;Genexine;Gilead Sciences;H. Lee Moffitt Cancer Center and Research Institute;Hoosier Cancer Research Network;Icahn School of Medicine at Mount Sinai;ImmunoGen;Incyte Corporation;Institut fuer Frauengesundheit;Institute of Cancer Research;M. D. Anderson Cancer Center;Massachusetts General Hospital;Mayo Clinic;Memorial Sloan-Kettering Cancer Center;Merck & Co;Merck Sharp & Dohme;National Cancer Center Hospital East;National Cancer Institute (France);National Cancer Institute (USA);Netherlands Cancer Institute;Northwestern University;NYU Langone Medical Center;Oslo University Hospital;Plexxikon;Providence Health & Services;Royal Marsden NHS Foundation Trust;Sarcoma Alliance for Research through Collaboration;Sellas Life Sciences Group;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;Spanish Breast Cancer Research Group;Syndax Pharmaceuticals;TG Therapeutics Inc;University Health Network;University of Alabama;University of Birmingham;University of California at Los Angeles;University of California at San Francisco;University of California San Diego;University of Colorado at Denver;University of Miami;University of Pittsburgh;University of Utah;University of Washington;Verastem Oncology;Wakayama Medical University;Washington University School of Medicine;Yale University;The Leukemia & Lymphoma Society Approved
PD-1 Pidilizumab American Cancer Society;Beth Israel Deaconess Medical Center;CureTech;Georgia Regents University;Hadassah Medical Organization;Northwestern University;The Ohio State University Comprehensive Cancer Center;University of Texas M. D. Anderson Cancer Center Approved
PD-1 Pimivalimab Jounce Therapeutics Approved
PD-1 Pradusinstobart MD Anderson Cancer Center;Lyvgen Biopharma Approved
PD-1 Prolgolimab Biocad Approved
PD-1 Pucotenlimab Taizhou Hanzhong Pharmaceuticals Approved
PD-1 Retifanlimab MacroGenics;Incyte Corporation;ZAI Lab Approved
PD-1 Rulonilimab Shandong New Time Pharmaceutical Co., LTD Phase 2/3
PD-1 Sasanlimab Pfizer Phase 3
PD-1 Serplulimab Henlix Biotech;Shanghai Henlius Biotech Approved
PD-1 Sintilimab Adimab;Innovent Biologics;Jiangsu Provincial Peoples Hospital;Sun Yat-Sen University Approved
PD-1 Spartalizumab Asan Medical Center;Dana-Farber Cancer Institute;Novartis;Novartis Oncology;Palobiofarma;Seoul National University Hospital Approved
PD-1 Tislelizumab BeiGene;Celgene Corporation Approved
PD-1 Toripalimab Fudan University;Peking University;Shanghai Junshi Biosciences;Sun Yat-Sen University Approved
PD-1 Zimberelimab Harbin Gloria Pharmaceuticals;WuXi Biologics;Arcus Biosciences;Beijing Cancer Hospital;Guangzhou Gloria Biosciences;Strata Oncology Approved
PD-1 x CTLA-4 Vudalimab Xencor Approved
PD-1, VEGF Ivonescimab Akesobio Australia Pty Ltd Phase 3
PD-L1 Adebrelimab Jiangsu Hengrui Medicine;Atridia Approved
PD-L1 Atezolizumab Amgen;ARCAGY/GINECO Group;BioLineRx;Chugai Pharmaceutical;Clovis Oncology;Dana-Farber Cancer Institute;Duke University;European Organisation for Research and Treatment of Cancer;Exelixis;Fondazione Michelangelo;GEICO (Spanish Ovarian Cancer Research Group);Genentech;GERCOR;Gradalis;H. Lee Moffitt Cancer Center and Research Institute;Immune Design;Incyte Corporation;Johns Hopkins University;Kaiser Permanente;M. D. Anderson Cancer Center;Memorial Sloan-Kettering Cancer Center;National Cancer Center (Korea);National Cancer Institute (USA);Netherlands Cancer Institute;Roche;Sanofi;Seattle Genetics;University Hospital Southampton NHS Foundation Trust;University Medical Center Groningen;University of California;University of California at San Francisco;University of Oklahoma;Yale University Approved
PD-L1 Avelumab AIO Studien gGmbH;Array BioPharma;Chong Kun Dang;Dana-Farber Cancer Institute;Debiopharm;eFFECTOR Therapeutics;EMD Serono;Forty Seven;Fred Hutchinson Cancer Research Center;Gachon University Gil Medical Center;Hellenic Cooperative Oncology Group;Hospices Civils de Lyon;Johannes Gutenberg-University Mainz;M. D. Anderson Cancer Center;Merck KGaA;National Cancer Institute (USA);National Cancer Institute Slovakia;Netherlands Cancer Institute;Pfizer;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;Syndax Pharmaceuticals;Transgene;University College London;University of Birmingham;University of California San Diego;University of Iowa;Vaccinex;Vanderbilt-Ingram Cancer Center;VAXIMM;Verastem Oncology;Washington University School of Medicine Approved
PD-L1 Cosibelimab Approved
PD-L1 Durvalumab Advaxis;AIO Studien gGmbH;AstraZeneca;Big Ten Cancer Research Consortium;Canadian Cancer Trials Group;Case Comprehensive Cancer Center;Celgene International SARL;Centre hospitalier de l'Universite de Montreal;Centre Leon Berard;Charite - Universitatsmedizin Berlin;Childrens Hospital Los Angeles;Dana-Farber Cancer Institute;Eli Lilly;Fondazione IRCCS Istituto Nazionale dei Tumori;GlaxoSmithKline;Gradalis;Grand Hopital de Charleroi;Grupo Espanol de Tumores Neuroendocrinos;Gustave Roussy;Immunocore;Innate Pharma;Institut Claudius Regaud;Juno Therapeutics;Kyoto Breast Cancer Research Network;Ludwig Institute for Cancer Research;M. D. Anderson Cancer Center;MedImmune;Memorial Sloan-Kettering Cancer Center;Mirati Therapeutics;Myriad Genetic Laboratories;National Cancer Institute (USA);National Health and Medical Research Council;Northwestern University;Pharmacyclics;Plexxikon;Radboud University;Samsung Medical Center;Spanish Oncology Genito-Urinary Group;Swiss Group for Clinical Cancer Research;UNC Lineberger Comprehensive Cancer Center;UNICANCER;University College London;University of Colorado at Denver;University of Kansas Medical Center;University of Maryland Greenbaum Cancer Center;University of Southern California;University of Sydney;University of Texas M. D. Anderson Cancer Center;VentiRx Pharmaceuticals;Washington University School of Medicine;Yale University;Yonsei University College of Medicine Approved
PD-L1 Sugemalimab Cstone Pharmaceuticals Approved
PD-L1 CBT Pharmaceuticals, Inc Phase 3
PD-L1, CTLA-4 Erfonrilimab Jiangsu Alphamab Biopharmaceuticals Co., Ltd Phase 3
PD-L1, TGF-β Retlirafusp alfa Jiangsu HengRui Medicine Co., Ltd. Phase 2/3 and Phase 3
PD-L1, VEGF Biotheus Inc. Phase 2/3
PDGFRA Olaratumab ImClone Systems;Eli Lilly;Institute for Clinical Oncological Research Approved
PDGFRB Rinucumab Regeneron Pharmaceuticals Discontinued
phosphatidylserine Bavituximab Avid Bioservices;IMV;Massachusetts General Hospital;Merck Sharp & Dohme;Peregrine Pharmaceuticals;University of Arizona;University of Texas Southwestern Medical Center;University of Texas M. D. Anderson Cancer Center Approved
PMSA Rosopatamab Weill Cornell Medical, Telix Pharmaceuticals Approved
PRLR Rolinsatamab AbbVie Approved
pro-GDF-8 Apitegromab Scholar Rock Approved
Protein substitute Valziflocept #N/A #N/A
PTK7 Cofetuzumab Stemcentrx;Indiana University;Pfizer;Stemcentrx Approved
PTPRC Iodine (131I) apamistamab #N/A #N/A
PVRL4 Enfortumab vedotin #N/A #N/A
Rabies virus spike glycoprotein Zamerovimab, mazorelvimab Synermore Biologics Co. Ltd. Phase 3
RABV Foravirumab Crucell;Sanofi Pasteur Discontinued
RABV Rafivirumab Crucell;Sanofi Pasteur Discontinued
RANKL Denosumab Amgen;Daiichi Sankyo Company;European Thoracic Oncology Platform;GlaxoSmithKline;Jules Bordet Institute;Melbourne Health;University Health Network Approved
RGMA Elezanumab AbbVie Approved
RHD Roledumab LFB Biotechnologies Approved
ROR1 Zilovertamab University of California;Oncternal Therapeutics;Merck Approved
ROR2 Ozuriftamab BioAtla Approved
RSPO3 Rosmantuzumab OncoMed Pharmaceuticals Discontinued
RSV Clesrovimab Merck Sharp & Dohme Corp. Phase 2/3 and Phase 3
RSV Gontivimab Ablynx Discontinued
RSV Motavizumab MedImmune Discontinued
RSV Nirsevimab AIMM Therapeutics;MedImmune Approved
RSV Palivizumab Approved
RSV Suptavumab Regeneron Pharmaceuticals Discontinued
RTN4 Atinumab Novartis Discontinued
RTN4 Ozanezumab GlaxoSmithKline Discontinued
S. aureus alpha toxin Suvratoxumab Biosynexus;GlaxoSmithKline;Regeneron Pharmaceuticals;MedImmune Approved
S. aureus ?-toxin Tosatoxumab Aridis Pharmaceuticals;Kenta Biotech Approved
SAA1 Birtamimab Neotope Biosciences;Onclave Therapeutics;Prothena Discontinued
SARS-CoV-2 Bamlanivimab Abcellera;Eli Lilly and Company;National Institute of Allergy and Infectious Diseases Approved
SARS-CoV-2 Casirivimab + imdevimab Approved
SARS-CoV-2 Enuzovimab ABL Bio;HiFiBiO Therapeutics Approved
SARS-CoV-2 Regdanvimab Approved
SARS-CoV-2 Sotrovimab Approved
SARS-CoV-2 Tixagevimab, cilgavimab Approved
SARS-CoV-2 AstraZeneca Phase 3
SDC1 Indatuximab Biotest AG Discontinued
SELP Crizanlizumab Selexys Pharmaceuticals;Novartis Approved
SELP Inclacumab Genmab;Roche;Global Blood Therapeutics Discontinued
SELP Torapsel #N/A #N/A
SEMA4D Pepinemab Bristol-Myers Squibb;Children's Oncology Group;Emory University;Merck KGaA;National Cancer Institute (USA);Teva Pharmaceutical Industries;UCLAs Jonsson Comprehensive Cancer Center;Vaccinex Approved
serotype IATS O11 Panobacumab Berna Biotech;Aridis Pharmaceuticals Approved
shiga toxin type 1 Pritoxaximab Sunol Molecular Corporation;Uniformed Services University of the Health Sciences;BELLUS Health;Taro Pharmaceuticals Inc Discontinued
shiga toxin type 2 Setoxaximab Sunol Molecular Corporation;Uniformed Services University of the Health Sciences;BELLUS Health;Taro Pharmaceuticals Inc Discontinued
SLAMF7 Azintuxizumab AbbVie Discontinued
SLAMF7 Elotuzumab AbbVie;Australasian Leukaemia & Lymphoma Group;Bristol-Myers Squibb;PDL BioPharma
SLC29A2 Clervonafusp alfa #N/A #N/A
SLC34A2 Lifastuzumab vedotin #N/A #N/A
SLC39A6 Ladiratuzumab Merck & Co;Quantum Leap Healthcare Collaborative;Seattle Genetics Approved
SLITRK6 Sirtratumab Astellas/Agensys;Seattle Genetics Approved
SNCA Cinpanemab Neurimmune Therapeutics;Biogen Discontinued
SNCA Exidavnemab AbbVie Approved
SNCA Prasinezumab Neotope Biosciences;Chugai Pharmaceutical;Prothena;Roche Approved
Sortilin Latozinemab Alector Phase 3
SOST Blosozumab Eli Lilly Approved
SOST Resugobart TBC Approved
SOST Romosozumab ChiroscienceGroup plc;Amgen;UCB
SOST Setrusumab MorphoSys;Novartis;Mereo BioPharma;Ultragenyx Pharmaceutical Inc Approved
STAB1 Bexmarilimab Faron Pharmaceuticals Approved
STEAP1 Vandortuzumab vedotin #N/A #N/A
TACSTD2 Sacituzumab IBC Pharmaceuticals;Immunomedics;University of Wisconsin Comprehensive Cancer Center;Yale University Approved
Tau Eisai Co., Ltd. Phase 2/3
Tetanus toxin Zhuhai Trinomab Biotechnology Co Ltd. Phase 3
TFPI Befovacimab na Approved
TFPI Concizumab Novo Nordisk Approved
TFRC Pabinafusp alfa #N/A #N/A
TGFB1 Lerdelimumab Cambridge Antibody Technology Discontinued
TGFB1 Linavonkibart Scholar Rock Approved
TGFB1 Metelimumab Cambridge Antibody Technology Discontinued
TGFbeta Fresolimumab Cambridge Antibody Technology;Baylor College of Medicine;Genzyme Corporation;Sanofi Genzyme Discontinued
TGM2 Zampilimab UCB Approved
Ticagrelor Bentracimab AstraZeneca Phase 3
TIGIT Domvanalimab Arcus Biosciences Phase 3
TIGIT Etigilimab OncoMed Pharmaceuticals Approved
TIGIT Ociperlimab BeiGene Phase 3
TIGIT Tamgiblimab Innovent Biologics Approved
TIGIT Tiragolumab Genentech Phase 3
TIGIT Vibostolimab Merck Sharp & Dohme Corp. Phase 3
TIM-3 Sabatolimab Novartis Phase 3
Tissue factor pathway inhibitor Concizumab Approved
Tissue factor pathway inhibitor Marstacimab Pfizer Phase 3
TLR2 Tomaralimab Opsona Therapeutics Approved
TNC Tenatumomab sigma-tau SpA Discontinued
TNF Adalimumab Abbvie;MedImmune;180 Life Sciences Approved
TNF Adalimumab beta #N/A #N/A
TNF Certolizumab pegol Approved
TNF Etanercept #N/A #N/A
TNF Golimumab Approved
TNF Infliximab Centocor;Janssen Biotech;Merck & Co;Mitsubishi Tanabe Pharma Corporation;National Jewish Medical and Research Center;Xian-Janssen
TNF Lenercept #N/A #N/A
TNF Onercept #N/A #N/A
TNF Opinercept #N/A #N/A
TNF Ozoralizumab Ablynx;Eddingpharm;Pfizer;Taisho Pharmaceutical Approved
TNF Pegsunercept #N/A #N/A
TNF Placulumab Domantis;Peptech;Arana Therapeutics;Teva Pharmaceutical Industries Discontinued
TNF Remtolumab Abbott Laboratories;Abbvie Discontinued
TNF Tulinercept #N/A #N/A
TNF-α receptor I Tanfanercept #N/A #N/A
TNFRSF10B Benufutamab Genmab;VU University Medical Center;iDD Biotech Approved
TNFRSF10B Conatumumab Amgen;Takeda Discontinued
TNFRSF10B Drozitumab Genentech Discontinued
TNFRSF10B Lexatumumab Cambridge Antibody Technology;Human Genome Sciences Discontinued
TNFRSF10B Tigatuzumab Daiichi Sankyo Company;University of Alabama at Birmingham Discontinued
TNFRSF10B Tilogotamab Genmab Approved
TNFRSF12A Enavatuzumab PDL BioPharma;Abbott Laboratories Discontinued
TNFRSF17 Ciltacabtagene autoleucel #N/A #N/A
TNFRSF17 Orvacabtagene autoleucel #N/A #N/A
TNFRSF17;CD3E Vonsetamig TBC Approved
TNFRSF4 Cudarolimab Innovent Biologics Discontinued
TNFRSF4 Revdofilimab AbbVie Approved
TNFRSF4 Tavolimab European Network of Gynaecological Oncological Trial Groups;MedImmune Discontinued
TNFRSF4 Telazorlimab Glenmark Pharmaceuticals Approved
TNFRSF4 Vonlerolizumab Genentech Discontinued
TNFRSF9 Evunzekibart Alligator Bioscience Approved
TNFSF11 Narlumosbart CSPC Pharmaceutical Group;Shanghai Jinmante Biotechnology Approved
TNFSF13 Atacicept #N/A #N/A
TNFSF13B Belimumab Assistance Publique Hopitaux de Paris;Cancer Trials Australia;GlaxoSmithKline;Hospital for Special Surgery;Human Genome Sciences;North Shore-Long Island Jewish Health System;University of Alabama at Birmingham;University of Pennsylvania;University of Wisconsin-Madison;Washington University School of Medicine;Cambridge Antibody Technology Approved
TNFSF13B Blisibimod #N/A #N/A
TNFSF13B Briobacept #N/A #N/A
TNFSF13B Telitacicept #N/A #N/A
TNFSF14 Quisovalimab Avalo Therapeutics Approved
TNFSF4 Amlitelimab Kymab Approved
Toll-like receptor 4 Paridiprubart NovImmune SA Phase 2/3
toxin A Actoxumab Bristol-Myers Squibb;Merck;University of Massachussets Medical School Discontinued
TPBG Naptumomab estafenatox #N/A #N/A
Trop-2 Datopotamab deruxtecan Daiichi-Sankyo Phase 3
Trop-2 Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. Phase 3
TSLP Tezepelumab Amgen;AstraZeneca;Bispebjerg Hospital;Lund University;MedImmune;University of Copenhagen;University of Newcastle in Australia Approved
TYRP1 Flanvotumab ImClone Systems;Eli Lilly Discontinued
VEGF Aflibercept #N/A #N/A
VEGF Ranibizumab Genentech;Manhattan Eye Ear & Throat Hospital;Novartis Ophthalmics;University of Bonn Approved
VEGF Suvemcitug Jiangsu Simcere Pharmaceutical Co., Ltd. Phase 3
VEGF Bio-Thera Solutions Phase 3
VEGF Mabwell (Shanghai) Bioscience Co., Ltd. Phase 2/3
VEGF Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd Phase 3
VEGFA Abicipar pegol #N/A #N/A
VEGFA Bevacizumab All Ireland Cooperative Oncology Research Group;ARCAGY/GINECO Group;Austrian Breast & Colorectal Cancer Study Group;Bayer;Beth Israel Deaconess Medical Center;Breast Cancer Research Foundation;Brigham and Women's Hospital;Bristol-Myers Squibb;Cancer and Leukemia Group B;Cancer Research UK;Chugai Pharmaceutical;Cincinnati Children's Hospital Medical Center;Dana-Farber Cancer Institute;Duke University;European Organisation for Research and Treatment of Cancer;European Thoracic Oncology Platform;Genentech;Hackensack University Medical Center;Hoosier Cancer Research Network;Indiana University School of Medicine;Japan Breast Cancer Research Group;M. D. Anderson Cancer Center;Massachusetts General Hospital;Medical University of South Carolina;Melanoma Research Foundation Breakthrough Consortium;Memorial Sloan-Kettering Cancer Center;National Cancer Institute (USA);National Comprehensive Cancer Network;NCIC Clinical Trials Group;North Central Cancer Treatment Group;NSABP Foundation;Ohio State University Medical Center;Peter MacCallum Cancer Centre;Roche;Royal Marsden NHS Foundation Trust;Sanofi;Sarcoma Alliance for Research through Collaboration;SCRI Development Innovations;South Eastern European Research Oncology Group;Spanish Cooperative Group for Digestive Tumour Therapy;Spanish Lung Cancer Group;Stanford University School of Medicine;SWOG;The Catalan Institute of Oncology;UNICANCER;University College London;University of Alabama at Birmingham;University of Arkansas System;University of California Davis;University of Iowa;University of Oklahoma;University of Tennessee;University of Texas M. D. Anderson Cancer Center;US Oncology Research;West German Study Group;Xijing Hospital Approved
VEGFA Brolucizumab ESBATech;Alcon Approved
VEGFA Conbercept #N/A #N/A
VEGFA Dilpacimab AbbVie Approved
VEGFA Faricimab Chugai Pharmaceutical;Roche Approved
VEGFA Vanucizumab Roche Discontinued
VEGFA Varisacumab Peregrine Pharmaceuticals;University of Texas Southwestern Medical Center;Affitech Research AS Discontinued
VEGFR2 Ramucirumab Dyax;AstraZeneca;Dana-Farber Cancer Institute;Eli Lilly;Merck Sharp & Dohme;University of Texas M. D. Anderson Cancer Center;Washington University School of Medicine Approved
VEGFR2 GeneScience Pharmaceuticals Co., Ltd. Phase 3
VIM Burfiralimab ImmuneMed Approved
VISTA Onvatilimab Janssen Research & Development Approved
VWF Caplacizumab Ablynx
Wnt ligands

In the Wnt/Frizzled pathway		 Ipafricept #N/A #N/A
Zaire Ebola virus Atoltivimab Regeneron Pharmaceuticals Discontinued
Zaire Ebola virus Cosfroviximab Mapp Biopharmaceutical;Public Health Agency of Canada;National Institute of Allergy and Infectious Diseases Approved
Zaire Ebola virus Larcaviximab Mapp Biopharmaceutical;Public Health Agency of Canada;National Institute of Allergy and Infectious Diseases Approved
Zaire Ebola virus Maftivimab Regeneron Pharmaceuticals Discontinued
Zaire Ebola virus Odesivimab Regeneron Pharmaceuticals Approved
Zaire Ebola virus Porgaviximab Mapp Biopharmaceutical;Public Health Agency of Canada;National Institute of Allergy and Infectious Diseases Discontinued
α4β7 integrin Vedolizumab Medical College of Wisconsin;Millennium Pharmaceuticals;Takeda;Takeda Oncology Approved